Rapport and Tenacia Secure $20M Upfront in $308M RAP-219 Collaboration in Greater China
Rapport granted Tenacia exclusive rights to develop and commercialize RAP-219 in Greater China, initiating Phase 3 trials in focal onset seizures in Q2 2026. Rapport will receive $20 million upfront, up to $308 million in milestones and mid-single-to-mid-teens tiered royalties on regional net sales.
1. Partnership Details
Rapport Therapeutics has granted Tenacia Biotechnology exclusive rights to develop and commercialize RAP-219 in mainland China, Hong Kong, Macau and Taiwan. RAP-219 is a potential first-in-class TARPγ8-specific AMPA receptor negative allosteric modulator targeting focal onset seizures and bipolar mania.
2. Financial Terms
Under the agreement, Rapport will receive a $20 million upfront cash payment and is eligible for up to approximately $308 million in development and commercialization milestones. The deal also includes mid-single-digit to mid-teens tiered royalties on net sales of RAP-219 in Greater China.
3. Development Timeline
Two global registrational trials of RAP-219 in focal onset seizures are planned, with the Phase 3 program expected to commence in the second quarter of 2026. Tenacia will lead the addition of Phase 3 clinical trial sites in China, leveraging its regional trial network.
4. Strategic Impact
The collaboration strengthens Rapport’s financial position with non-dilutive capital while accelerating RAP-219 development and regional market access. Rapport retains global rights outside Greater China, enabling continued investment in its broader precision neuroscience pipeline.